Investigating how ceramide metabolism affects cancer spread and treatment resistance in triple-negative breast cancer.
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
This study is looking at how a substance called ceramide affects the growth and treatment response of triple-negative breast cancer, with the goal of finding new ways to help patients respond better to immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10932439 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of ceramide metabolism in triple-negative breast cancer (TNBC), particularly how it influences the spread of cancer and resistance to immunotherapy. The study aims to explore the mechanisms by which tumor cells reduce PD-L1 expression, which is crucial for the effectiveness of immunotherapy. By examining the relationship between ceramide levels and cancer cell behavior, the research seeks to identify potential therapeutic targets that could enhance treatment responses for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are facing challenges with treatment resistance.
Not a fit: Patients with non-triple-negative breast cancer or those who are not currently undergoing immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with triple-negative breast cancer, potentially enhancing their response to immunotherapy.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Ogretmen, Besim — Medical University of South Carolina
- Study coordinator: Ogretmen, Besim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.